STGen Bio to Participate in 'BIX 2023'... "Strengthening Networking"

STGENE Bio announced on the 11th that it will participate in 'BIOPLUS-INTERPHEX KOREA 2023 (BIX 2023)', held for three days from the 12th to the 14th at COEX in Gangnam-gu, Seoul.

Booth of STGen Bio to be featured at 'BIOPLUS-INTERPHEX KOREA (BIX) 2023'. [Image provided by STGen Bio]

BIX 2023, co-hosted by the Korea Bio Association and Reed Exhibitions Korea (RX Korea), is an event consisting of booth exhibitions, conferences, partnering, and open innovation. This year, more than 200 pharmaceutical and bio companies from home and abroad are expected to attend.

STGENE Bio will set up a solo booth in the Contract Manufacturing Organization (CMO)/Contract Development and Manufacturing Organization (CDMO) special pavilion for the second consecutive year following last year. This year, it will participate as a sponsor of BIX 2023 to promote its activities and build business networking with global pharmaceutical companies and potential partners through a 1:1 partnering platform.

Earlier, STGENE Bio participated with a solo booth at Interphex-Tokyo 2023 held in Tokyo, Japan, from the 5th to the 7th, expanding its global partnerships.

STGENE Bio, a subsidiary of Dong-A Socio Holdings, is a specialized CMO and CDMO company. It possesses production facilities for active pharmaceutical ingredients such as biosimilars and recombinant proteins, as well as finished drug production facilities in the form of prefilled syringes (PFS), a type of prefilled syringe.

STGENE Bio plans to expand its business areas to include bispecific antibodies, antibody-drug conjugates (ADC), and cell and gene therapies (CGT). Since last year, based on a business agreement with Protium Science, a specialized company in contract development and analysis of biopharmaceuticals (CDAO), it has been providing one-stop CDMO services.

An STGENE Bio official said, "Starting with Interphex Tokyo 2023 and participating in BIX Korea, we plan to widely introduce STGENE Bio’s technological capabilities to global partners," adding, "STGENE Bio will continue to participate in domestic and international pharmaceutical and bio exhibitions to strengthen business networking with potential partners."

This content was produced with the assistance of AI translation services.